Cullinan Therapeutics (CGEM) Cash & Equivalents: 2020-2023
Historic Cash & Equivalents for Cullinan Therapeutics (CGEM) over the last 3 years, with Sep 2023 value amounting to $466.4 million.
- Cullinan Therapeutics' Cash & Equivalents fell 19.03% to $466.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $466.4 million, marking a year-over-year decrease of 19.03%. This contributed to the annual value of $156.2 million for FY2022, which is 161.24% up from last year.
- Per Cullinan Therapeutics' latest filing, its Cash & Equivalents stood at $466.4 million for Q3 2023, which was down 5.16% from $491.8 million recorded in Q2 2023.
- In the past 5 years, Cullinan Therapeutics' Cash & Equivalents ranged from a high of $611.0 million in Q2 2022 and a low of $59.8 million during Q4 2021.
- In the last 3 years, Cullinan Therapeutics' Cash & Equivalents had a median value of $390.7 million in 2023 and averaged $357.2 million.
- As far as peak fluctuations go, Cullinan Therapeutics' Cash & Equivalents plummeted by 64.46% in 2021, and later surged by 394.06% in 2022.
- Over the past 4 years, Cullinan Therapeutics' Cash & Equivalents (Quarterly) stood at $168.2 million in 2020, then tumbled by 64.46% to $59.8 million in 2021, then skyrocketed by 161.24% to $156.2 million in 2022, then dropped by 19.03% to $466.4 million in 2023.
- Its Cash & Equivalents stands at $466.4 million for Q3 2023, versus $491.8 million for Q2 2023 and $390.7 million for Q1 2023.